…
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Alcon AG is a global eye-care company that develops, manufactures and sells surgical systems, intraocular lenses and vision-care consumables. Long-term growth may be driven by aging populations increasing cataract and refractive procedures, recurring consumables revenue and innovation in premium lenses and surgical platforms, and the company appears positioned as a market leader with global reach.
Principal risks include intense competition and pricing pressure, sensitivity of surgical volumes to economic and healthcare cycles, regulatory and manufacturing-compliance challenges, and supply-chain and currency exposure.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 1160.00M | 1256.00M | 832.00M | 463.00M | 418.00M |
| Minority interest | 0.00M | - | - | - | - |
| Net income | 980.00M | 1018.00M | 974.00M | 335.00M | 376.00M |
| Selling general administrative | 3449.00M | 3250.00M | 3209.00M | 3068.00M | 3057.00M |
| Gross profit | 5745.00M | 5512.00M | 5247.00M | 4748.00M | 4652.00M |
| Reconciled depreciation | 1335.00M | 1228.00M | 1221.00M | 1123.00M | 1219.00M |
| Ebit | 1160.00M | 1448.00M | 1021.00M | 616.59M | 539.14M |
| Ebitda | 2351.00M | 2676.00M | 2242.00M | 1776.43M | 1760.74M |
| Depreciation and amortization | 1191.00M | 1228.00M | 1221.00M | 1159.84M | 1221.59M |
| Operating income | 1360.00M | 1413.00M | 1039.00M | 672.00M | 580.00M |
| Other operating expenses | 9041.00M | 8498.00M | 8416.00M | 8045.00M | 7711.00M |
| Interest expense | 204.00M | 192.00M | 189.00M | 134.00M | 120.00M |
| Tax provision | 180.00M | 238.00M | -142.00M | 128.00M | 42.00M |
| Interest income | 74.00M | 84.00M | 45.00M | 16.00M | 146.00M |
| Net interest income | -142.00M | -120.00M | -155.00M | -146.00M | -162.00M |
| Income tax expense | 180.00M | 238.00M | -142.00M | 128.00M | 42.00M |
| Total revenue | 10401.00M | 9911.00M | 9455.00M | 8717.00M | 8291.00M |
| Total operating expenses | 4385.00M | 4099.00M | 4208.00M | 4076.00M | 4072.00M |
| Cost of revenue | 4656.00M | 4399.00M | 4208.00M | 3969.00M | 3639.00M |
| Total other income expense net | -200.00M | -157.00M | -207.00M | -209.00M | -162.00M |
| Net income from continuing ops | 980.00M | 1018.00M | 974.00M | 335.00M | 376.00M |
| Net income applicable to common shares | - | - | - | 335.00M | 376.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 31555.00M | 30347.00M | 29614.00M | 29209.00M | 27999.00M |
| Intangible assets | 9006.00M | 8587.00M | 9060.00M | 9689.00M | 8765.00M |
| Other current assets | 509.00M | 129.00M | 241.96M | 418.00M | 95.00M |
| Total liab | 9520.00M | 8794.00M | 8990.00M | 9532.00M | 8743.00M |
| Total stockholder equity | 22034.00M | 21553.00M | 20617.02M | 19677.00M | 19256.00M |
| Deferred long term liab | - | - | - | - | 557.00M |
| Other current liab | 1468.00M | 1100.16M | 1338.20M | 1664.00M | 1287.00M |
| Common stock | 20.00M | 20.00M | 19.99M | 20.00M | 20.00M |
| Capital stock | - | 20.00M | 20.00M | 20.00M | 20.00M |
| Retained earnings | - | - | - | - | 19356.00M |
| Other liab | - | - | - | 1850.00M | 1966.00M |
| Good will | 9256.00M | 8946.00M | 8926.00M | 8970.00M | 8905.00M |
| Other assets | - | - | -10.03M | 833.00M | 1365.00M |
| Cash | 1527.00M | 1829.00M | 1094.00M | 980.00M | 1575.00M |
| Total current liabilities | 3049.00M | 2278.00M | 2479.16M | 2782.00M | 2472.00M |
| Current deferred revenue | - | 72.84M | -0.84M | 89.00M | 108.00M |
| Net debt | 3719.00M | 3307.00M | 4041.00M | 4088.00M | 2904.00M |
| Short term debt | 655.00M | 169.00M | 216.00M | 168.00M | 174.00M |
| Short long term debt | - | 101.00M | 135.00M | 97.00M | 107.00M |
| Short long term debt total | 5246.00M | 5136.00M | 5135.00M | 5068.00M | 4479.00M |
| Other stockholder equity | - | - | - | 19657.00M | 19236.00M |
| Property plant equipment | - | - | - | 4416.00M | 4083.00M |
| Total current assets | 6449.00M | 6309.00M | 5647.00M | 5193.00M | 5386.00M |
| Long term investments | - | 751.00M | 319.00M | 108.00M | 52.00M |
| Net tangible assets | - | - | - | 1018.00M | 2143.00M |
| Short term investments | 80.00M | 1.00M | 7.00M | -179.00M | 3.00M |
| Net receivables | 1942.00M | 2082.00M | 1981.33M | 1686.00M | 1814.00M |
| Long term debt | - | 4538.00M | 4594.00M | 4541.00M | 3966.00M |
| Inventory | 2391.00M | 2268.00M | 2322.00M | 2109.00M | 1899.00M |
| Accounts payable | 926.00M | 773.00M | 811.00M | 861.00M | 903.00M |
| Accumulated other comprehensive income | 22014.00M | 21533.00M | 20597.02M | 19657.00M | 19236.00M |
| Non currrent assets other | 855.00M | 495.00M | 496.15M | 243.00M | 399.00M |
| Non current assets total | 25106.00M | 24038.00M | 23967.00M | 24016.00M | 22613.00M |
| Capital lease obligations | 509.00M | 497.00M | 406.00M | 430.00M | 406.00M |
| Long term debt total | - | - | - | - | 4305.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 22.00M | -1167.00M | -1094.00M | -1865.00M | -18.00M |
| Change to liabilities | - | - | - | -48.00M | 60.00M |
| Total cashflows from investing activities | -1344.00M | -1167.00M | -1094.00M | -1865.00M | -1198.00M |
| Net borrowings | -31.00M | -137.00M | -7.00M | 208.00M | -63.00M |
| Total cash from financing activities | -1119.00M | -322.00M | -211.00M | -8.00M | -123.00M |
| Change to operating activities | - | - | - | -192.00M | 88.00M |
| Net income | 980.00M | 1018.00M | 974.00M | 335.00M | 376.00M |
| Change in cash | -149.00M | 582.00M | 114.00M | -595.00M | 18.00M |
| Begin period cash flow | 1676.00M | 1094.00M | 980.00M | 1575.00M | 1557.00M |
| End period cash flow | 1527.00M | 1676.00M | 1094.00M | 980.00M | 1575.00M |
| Total cash from operating activities | 2271.00M | 2077.00M | 1388.00M | 1217.00M | 1345.00M |
| Depreciation | 1191.00M | 1228.00M | 1221.00M | 1123.00M | 1219.00M |
| Other cashflows from investing activities | -109.00M | -205.00M | -177.30M | - | -18.00M |
| Dividends paid | 166.00M | 130.00M | 116.00M | -100.00M | -54.00M |
| Change to inventory | -156.00M | -47.00M | -289.26M | -217.00M | -326.00M |
| Change to account receivables | -129.00M | -55.00M | -117.41M | -164.00M | -198.00M |
| Sale purchase of stock | -723.00M | -47.00M | -49.00M | - | - |
| Other cashflows from financing activities | -134.00M | -55.00M | -39.00M | 2428.00M | 3.00M |
| Change to netincome | - | - | - | 380.00M | 128.00M |
| Capital expenditures | 543.00M | 670.00M | 851.00M | 745.00M | 1180.00M |
| Change in working capital | -300.00M | -189.00M | -431.22M | -527.00M | -314.00M |
| Stock based compensation | 162.00M | 150.00M | 144.00M | 140.00M | 138.00M |
| Other non cash items | 400.00M | -368.00M | -377.78M | 18.00M | -116.00M |
| Free cash flow | 1728.00M | 1407.00M | 537.00M | 472.00M | 165.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALC Alcon AG |
-1.66 2.24% |
72.40 | 51.73 | 16.92 | 3.02 | 1.52 | 3.35 | 13.34 |
| ISRG Intuitive Surgical Inc |
0.21 0.05% |
450.25 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
-11.76 5.48% |
202.74 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-3.10 2.95% |
101.85 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
1.91 0.90% |
214.52 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
| Name | Title | Year Born |
|---|---|---|
| Mr. F. Michael Ball | Exec. Chairman | 1955 |
| Mr. David J. Endicott | CEO & Director | 1965 |
| Mr. Arthur B. Cummings M.D. | Exec. Director | 1962 |
| Mr. Timothy C. Stonesifer | Chief Financial Officer | 1967 |
| Margaret Buckley | Chief Accounting Officer | NA |
| Dr. Franck Leveiller | Sr. VP, Head of Global R&D and Chief Scientific Officer | NA |
| Ms. Sue-Jean Lin | Sr. VP & Chief Information and Transformation Officer | 1969 |
| Mr. Royce R. Bedward | Sr. VP, Gen. Counsel & Corp. Sec. | 1966 |
| Mr. Laurent Attias | Head of Corp. Devel., Strategy, BD&L and M&A | 1968 |
| Ms. Kimberly Martin | Sr. VP & Chief HR Officer | 1975 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.